San Francisco Bay area adult glioma survival study

描述(由申请人提供)：对相关肿瘤和患者特征的识别可能有助于为每个胶质瘤患者选择最佳治疗方案，有助于根据统一的预后为临床试验增强同质亚组的清晰度，以便快速进行治疗评估，并为患者提供更好的预后信息。为了确定相关特征，这项研究将检查生存率与几个具有潜在预后价值的肿瘤标志物、已知的预后患者特征(如年龄)以及那些尚未研究的与胶质瘤预后相关的因素，包括DNA修复和致癌物代谢基因的各种多态、个人和家族病史、诊断前的饮食、吸烟和饮酒，以及其他人口统计学因素。这项研究的具体目标是：(1)确定2004年的生命状况和相关的治疗信息，或1991-94至1997-99年间诊断的881例成人脑胶质瘤患者，并作为旧金山湾区成人脑胶质瘤的一部分进行访谈 研究(正在进行的NCI资助的成人胶质瘤遗传和分子流行病学研究)。(2)使用COX回归和递归分割分析来确定生存率作为已建立的、潜在的和尚未研究的预后指标的函数；(3)在UCSF的临床试验方案中验证AIM 2在新诊断的GM患者中获得的结果。我们将收集2002年7月1日至2006年6月30日在加州大学旧金山分校神经肿瘤科就诊的新诊断患者的血液、口腔和肿瘤标本以及临床和简要问卷数据。在AIM 2中确定的有希望的标记物将在临床试验方案中对100例GM病例进行检测，并纳入验证生存分析。这项研究提供了一个独特的机会，可以利用流行病学危险因素数据、构成DNA样本和肿瘤标记物数据来检查大量基于人群的患者的存活率，从而初步评估标记物，然后将这些标记物纳入前瞻性临床试验进行验证。

DESCRIPTION (provided by applicant): The identification of relevant tumor and patient characteristics is likely to aid in choosing the best treatments for each glioma patient, in enhancing definition of homogeneous subgroups for clinical trials based on uniform prognosis for rapid treatment evaluation, and in providing better prognostic information to patients. To identify relevant characteristics, this study will examine survival in relationship to several tumor markers with potential prognostic value, patient characteristics known to be prognostic (such as age), and those factors as yet unstudied in relation to glioma prognosis including a variety of polymorphisms in DNA repair and carcinogen metabolizing genes, personal and family medical histories, diet, smoking and alcohol consumption prior to diagnosis, and other demographic factors. The study's specific aims are to: (1) Determine vital status through 2004 and relevant treatment information or 881 population based adult onset glioma cases diagnosed between 1991-94 and 1997-99 and interviewed as part of the San Francisco Bay Area Adult Glioma Study (an ongoing NCI funded study of the genetic and molecular epidemiology of adult glioma). (2) Use Cox regressions and recursive partitioning analysis to determine survival as a function of both established, potential, and as yet unstudied prognostic indicators; (3) Validate results obtained from aim 2 in newly diagnosed GM patients on clinical trial protocols at UCSF. We will collect blood, buccal and tumor specimens and clinical and brief questionnaire data for newly diagnosed patients seen at the UCSF Neuro-Oncology Service from July 1, 2002-June 30, 2006. Promising markers identified in aim 2 will be assayed for 100 of these GM cases on clinical trial protocols and incorporated into a validation survival analysis. This study provides a unique opportunity to examine survival in a large, population-based group of patients with epidemiologic risk factor data, constitutive DNA specimens, and tumor marker data and thus to preliminarily evaluate markers that will then be incorporated into prospective clinical trials for validation.